par Pozniak, Joanna;Pedri, Dennis;Landeloos, Ewout;Van Herck, Yannick;Antoranz, Asier;Vanwynsberghe, Lukas;Nowosad, Ada;Roda, Niccolò;Makhzami, Samira
;Bervoets, Greet;Maciel, Lucas Ferreira;Pulido-Vicuña, Carlos Ariel;Pollaris, Lotte;Seurinck, Ruth;Zhao, Fang;Flem-Karlsen, Karine;Damsky, William;Chen, Limin;Karagianni, Despoina;Cinque, Sonia;Kint, Sam;Vandereyken, Katy;Rombaut, Benjamin;Voet, T.;Vernaillen, Frank;Annaert, Wim;Lambrechts, Diether;Boecxstaens, Veerle;Saeys, Yvan;van den Oord, Joost;Bosisio, Francesca;Karras, Panagiotis
;Shain, Alan Hunter;Bosenberg, Marcus;Leucci, Eleonora
;Paschen, Annette;Rambow, Florian;Bechter, Oliver;Marine, Jean-Christophe 
Référence Cell, 187, 1, page (166-183.e25)
Publication Publié, 2024-01-01
;Bervoets, Greet;Maciel, Lucas Ferreira;Pulido-Vicuña, Carlos Ariel;Pollaris, Lotte;Seurinck, Ruth;Zhao, Fang;Flem-Karlsen, Karine;Damsky, William;Chen, Limin;Karagianni, Despoina;Cinque, Sonia;Kint, Sam;Vandereyken, Katy;Rombaut, Benjamin;Voet, T.;Vernaillen, Frank;Annaert, Wim;Lambrechts, Diether;Boecxstaens, Veerle;Saeys, Yvan;van den Oord, Joost;Bosisio, Francesca;Karras, Panagiotis
;Shain, Alan Hunter;Bosenberg, Marcus;Leucci, Eleonora
;Paschen, Annette;Rambow, Florian;Bechter, Oliver;Marine, Jean-Christophe 
Référence Cell, 187, 1, page (166-183.e25)
Publication Publié, 2024-01-01
Article révisé par les pairs
| Résumé : | To better understand intrinsic resistance to immune checkpoint blockade (ICB), we established a comprehensive view of the cellular architecture of the treatment-naive melanoma ecosystem and studied its evolution under ICB. Using single-cell, spatial multi-omics, we showed that the tumor microenvironment promotes the emergence of a complex melanoma transcriptomic landscape. Melanoma cells harboring a mesenchymal-like (MES) state, a population known to confer resistance to targeted therapy, were significantly enriched in early on-treatment biopsies from non-responders to ICB. TCF4 serves as the hub of this landscape by being a master regulator of the MES signature and a suppressor of the melanocytic and antigen presentation transcriptional programs. Targeting TCF4 genetically or pharmacologically, using a bromodomain inhibitor, increased immunogenicity and sensitivity of MES cells to ICB and targeted therapy. We thereby uncovered a TCF4-dependent regulatory network that orchestrates multiple transcriptional programs and contributes to resistance to both targeted therapy and ICB in melanoma. |



